智通财经APP讯，翰森制药(03692)公布，集团创新药阿美乐®新增一项适应症、昕越®新增两项适应症成功纳入新版《国家基本医疗保险、工伤保险和生育保险药品目录(2026年)》，新版国家目录将于2027年1月1日正式实施。
此外，集团创新药甲磺酸阿美替尼片(商品名：阿美乐®)其余四项适应症、伊奈利珠单抗注射液(商品名：昕越®)其余一项适应症及甲磺酸氟马替尼片(商品名：豪森昕福®)均续约纳入2026国家医保目录，聚乙二醇洛塞那肽注射液(商品名：孚来美®)续约纳入2026国家医保目录并扩展医保支付范围;培莫沙肽注射液(商品名：圣罗莱®)和艾米替诺福韦片(商品名：恒沐®)目前均尚在国家医保目录协议期内，协议有效期至2027年12月31日;吗啉硝唑氯化钠注射液(商品名：迈灵达®)已纳入国家医保常规目录乙类。集团已上市创新药所有获批适应症均已纳入医保目录，有助于进一步提高各创新药在患者中的可负担性和可及性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.